Bile Acid Diarrhoea: What Experts Say About Diagnosis and Treatment — A Guide for Patients

Table of Contents

• Key Points
• Background: What Is Bile Acid Diarrhoea?
• Study Methods: How the Expert Survey Was Conducted
• Key Findings: What Experts Call This Condition
• Associated Conditions: Who Gets BAD?
• Symptoms: When Should Testing Be Considered?
• Diagnostic Tests: How BAD Is Confirmed
• Testing in Specific Clinical Situations
• Management: How BAD Is Treated
• Expected Response Rates by Severity
• Follow-Up and Improving Patient Experience
• Clinical Implications: What This Means for Patients
• Study Limitations: What This Survey Couldn't Prove
• Recommendations: Actionable Advice for Patients
• Frequently Asked Questions
• Source Information

Key Points

• Bile acid diarrhoea is common, underdiagnosed, and often delayed by more than 5 years before diagnosis.
• SeHCAT testing was preferred by 100% of surveyed experts to confirm BAD before treatment.
• For severe BAD, treatment response exceeds 70% according to virtually all experts.
• Experts recommend increasing dose, adding loperamide, switching sequestrants, or a low fat diet for incomplete response.
• If you have IBS-D, functional diarrhoea, or diarrhoea after gallbladder removal, consider asking about BAD testing.

Background: What Is Bile Acid Diarrhoea?

Bile acid diarrhoea (BAD) is a medical condition that occurs when too many bile acids reach the colon (large intestine). Bile acids are digestive fluids produced by the liver and stored in the gallbladder. Normally, they help digest fats in the small intestine and are then reabsorbed in the final section of the small intestine, called the terminal ileum. When this reabsorption process fails—or when the liver produces too many bile acids—the excess spills into the colon, where it triggers fluid and electrolyte secretion, leading to diarrhoea.

Doctors have recognised this condition for over 50 years. It was originally called "cholerheic enteropathy," and it has also been known as bile acid malabsorption (BAM) or bile salt malabsorption. Today, the preferred term is BAD, and it is increasingly understood to cause a wide range of gastrointestinal symptoms—not just diarrhoea.

Patients with BAD often experience a variety of troublesome symptoms, including:

• Intermittent or persistent diarrhoea
• Increased bowel frequency
• Urgency (feeling like you must rush to the toilet)
• Nocturnal defaecation (waking up at night to pass stool)
• Excessive flatulence
• Abdominal pain
• Faecal incontinence (involuntary loss of stool)

BAD can arise from several causes. In some patients, it follows ileal resection (surgical removal of part of the terminal ileum), active Crohn's disease, cancer chemotherapy, or pelvic irradiation (radiation therapy). This is called secondary BAD. In other patients—those with no identifiable cause—the condition is called primary or idiopathic BAD. Research shows that primary BAD forms a subset of patients diagnosed with chronic functional diarrhoea or irritable bowel syndrome with predominant diarrhoea (IBS-D). Most of these patients have no defect in bile acid absorption itself; rather, the problem appears to be hepatic (liver) overproduction of bile acids. This overproduction has been linked to increased blood levels of a bile acid precursor called C4 (7α-OH-4-cholesten-3-one) and to impaired feedback from a hormone called fibroblast growth factor 19 (FGF19), which is produced in the ileum.

Despite being relatively common, BAD is often underdiagnosed. A survey by patient groups has shown poor recognition among healthcare professionals, with diagnostic delay often exceeding 5 years. This means many patients suffer unnecessarily for long periods without a proper diagnosis or effective treatment—a large unmet need in symptom control.

Study Methods: How the Expert Survey Was Conducted

The UK Bile Acid Related Diarrhoea Network (UK-BARDN) was established in 2017 as a forum for researchers who had recently published work on BAD/BAM. To better understand current practice and provide guidance, the network conducted an online survey of its clinical members.

The researchers identified areas of debate in the diagnosis and management of BAD and BAM, then developed a survey consisting of 24 questions covering terminology, symptoms, diagnostic tests, treatment approaches, and follow-up care. Answers were collected using Survey Monkey, an online survey platform, and were analysed statistically.

The survey link was sent at the end of 2018 to 21 clinicians in UK-BARDN. All participants had published research on BAD. At the time of the survey, 95% held a consultant post (senior specialist position) in the National Health Service (NHS)—this has since become 100%. A remarkable 100% response rate was achieved.

The experts who responded were highly experienced:

• 85% had diagnosed more than 50 patients with BAD
• 48% had diagnosed more than 100 patients
• Collectively, they had treated in excess of 1,000 patients with BAD

For statistical analysis, comparisons of proportions between groups were made using Fisher's exact test. A p value of 0.05 was taken as statistically significant—meaning there was less than a 5% probability that the findings occurred by chance alone.

Key Findings: What Experts Call This Condition

Because the terminology for this condition has varied over the years, the researchers wanted to see whether there was a majority preference for specific terms. The survey found that:

• 57% of respondents preferred the term "bile acid diarrhoea" (BAD)
• 14% preferred "bile acid malabsorption" (BAM)
• 29% used either term depending on the clinical circumstances

When classifying the different types of BAD, 89% preferred the classification of "primary or secondary." The second preference was the older system of "types 1, 2, and 3" (where type 1 is ileal malabsorption, type 2 is idiopathic, and type 3 is secondary to other gastrointestinal disorders), and the third choice was "overproduction or malabsorption."

Associated Conditions: Who Gets BAD?

The experts were asked which specific conditions they recognised as being associated with a higher incidence of BAD. The majority identified the following as recognised associations:

• Ileal resection (surgical removal of part of the small intestine)
• Crohn's disease
• Right hemicolectomy (surgical removal of the right side of the colon)
• Cholecystectomy (gallbladder removal)
• Pelvic or abdominal radiotherapy (radiation therapy for cancer)
• Irritable bowel syndrome with predominant diarrhoea (IBS-D)
• Functional bowel disease with diarrhoea
• Microscopic colitis
• Bariatric surgery (weight loss surgery)
• Small intestinal bacterial overgrowth (SIBO)
• Partial gastrectomy (surgical removal of part of the stomach)

This wide-ranging list highlights that BAD is not a single-disease problem but rather a condition that can arise from many different underlying causes. If you have any of these conditions and experience chronic diarrhoea, BAD may be worth investigating.

Symptoms: When Should Testing Be Considered?

The experts were asked which specific symptoms would lead them to consider ordering a diagnostic test for BAD. The results are shown in the table below, which summarises the percentage of respondents who routinely considered testing for each symptom:

Interestingly, the majority of respondents did not routinely consider testing for the following symptoms:

• Weight gain or weight loss combined with loose stools
• Variable loose and hard stools
• Anal faecal soiling
• Frequency between 1 and 3 times/day
• Abdominal pain associated with, or relieved by, defaecation
• Specific yellow or green coloured stools

This does not mean these symptoms are never associated with BAD—rather, they were not the symptoms that would routinely trigger a diagnostic test in the experts' experience. Loose stools and high frequency were the strongest indicators.

Diagnostic Tests: How BAD Is Confirmed

Several methods exist for diagnosing BAD, and the survey asked experts which tests they preferred and use in practice. Here is what they found:

SeHCAT testing was the clear favourite. All respondents (100%) selected SeHCAT as a diagnostic test for BAD, and 95% said it was the test they used most frequently. SeHCAT (tauroselcholic acid) is a nuclear medicine test developed in the 1980s. It involves swallowing a capsule containing a small amount of radioactive selenium-labelled bile acid (75Se-radiolabelled 23-selena-25-homotaurocholate). A scan is performed on day 1 and again on day 7 to measure how much of the labelled bile acid is retained in the body. Low retention means excess bile acids are escaping into the colon—confirming BAD.

The second most popular diagnostic approach was a therapeutic trial—prescribing a bile acid sequestrant (BAS) medication and seeing whether symptoms improve—which was chosen by 85% of respondents as a diagnostic method. Blood tests were less commonly recognised: 61% recognised FGF19 testing and 57% recognised C4 testing as diagnostic options.

SeHCAT has been shown in previous research to predict response to several treatments, including:

• Colestyramine (a bile acid sequestrant)
• Colestipol (another sequestrant)
• Colesevelam (a newer sequestrant)
• A low fat diet
• Obeticholic acid (a medication that reduces bile acid production)

SeHCAT use in the UK has grown substantially, especially in the last decade. However, SeHCAT is only available in certain countries and is not licensed in the USA, which has greatly limited understanding of its value internationally, hindered recognition of BAD, and slowed the development of new drugs and consensus guidelines.

The survey also asked about access to testing. Experts thought it appropriate for hospitals to have access to SeHCAT, FGF19, C4, and faecal (stool) tests. Importantly, 50% of respondents thought general practitioners (GPs—family doctors) should have access to SeHCAT testing, which could help reduce diagnostic delays. Hospitals and GPs were both thought appropriate for conducting therapeutic trials.

Testing in Specific Clinical Situations

The survey then asked about the actual use of SeHCAT and therapeutic trials in specific patient scenarios. The experts were asked to rate how often they would request each test using the following scale: "Always" (>99% of the time), "Usually" (>70%), "Sometimes" (30–70%), "Rarely" (<30%), or "Never" (<1%).

Functional Diarrhoea

In patients with functional diarrhoea (reflecting the wording of the current Rome IV criteria—episodic diarrhoea for more than 6 months without predominant abdominal pain or bothersome bloating, with more than 25% of stools being Bristol Stool Form Scale types 6 or 7, which are mushy or watery), 80% of experts would usually request SeHCAT. This was significantly more than the 10% who would usually use a therapeutic trial (p<0.001—highly statistically significant).

Irritable Bowel Syndrome with Diarrhoea (IBS-D)

In patients with features of IBS-D (episodic diarrhoea in the last 3 months, with more than 25% of stools being types 6/7 and less than 25% being types 1/2—hard lumps), SeHCAT was usually requested by 70% of respondents. This was also significantly more than use of a therapeutic trial (p<0.002).

Irritable Bowel Syndrome with Mixed Bowel Habit

In IBS with mixed bowel habit (variable bowel habit with more than 25% of stools being type 6/7 and more than 25% being type 1/2), SeHCAT was usually requested by 43%, at least sometimes (more than 30% of the time) by 62%, but rarely used by 38%.

Irritable Bowel Syndrome with Constipation

In IBS with constipation (variable bowel habit with less than 25% of stools being type 6/7 and more than 25% being type 1/2), SeHCAT was rarely used by 50% of respondents—as would be expected, since BAD is a diarrhoea-predominant condition.

Postcholecystectomy Diarrhoea

In patients with diarrhoea starting after gallbladder removal (cholecystectomy)—with more than 25% of stools being types 6/7—SeHCAT was usually used by 71% of respondents. A therapeutic trial would usually be used by 36% (p=0.08, a difference that did not reach statistical significance). However, when including those who would use these tests "sometimes," SeHCAT use was significantly greater than trial use (90% vs 50%, p=0.02).

Crohn's Disease with Ileal Resection

For patients with Crohn's disease, diarrhoea, and an ileal resection of 50–100 cm:

• If inflammatory markers (serum C-reactive protein and faecal calprotectin) were negative, a therapeutic trial would be used roughly as often as SeHCAT by half the respondents. Either test was considered appropriate at least sometimes by at least 70%.
• If inflammatory markers were raised, SeHCAT was used by over 50% at least sometimes, but use of a therapeutic trial was much less likely than when inflammatory markers were negative (p=0.02).

The experts noted that in Crohn's patients with ileal resection and negative inflammatory markers, accumulated data shows a greater than 90% likelihood of an abnormal SeHCAT result, which explains why a trial of therapy is considered reasonable in this specific group.

Management: How BAD Is Treated

Once a diagnosis of BAD is confirmed by SeHCAT testing, the next step is treatment. The survey revealed how experts approach treatment and what their recommendations are.

When to Offer Treatment

The likelihood of offering treatment varied according to the SeHCAT result—specifically, the 7-day retention percentage. Lower retention means more severe disease. The findings are illustrated in Figure 2 of the original paper:

• SeHCAT 0%–5% (severe disease): 100% of experts would always treat
• SeHCAT 5%–10% (moderate disease): 86% would always treat, and the rest would usually treat
• SeHCAT 10%–15% (mild disease): 86% would usually treat
• SeHCAT 15%–20% (borderline): 80% would sometimes offer treatment
• SeHCAT over 20% (normal): treatment was rarely offered

This demonstrates a clear, evidence-based approach: the lower the SeHCAT retention, the more confident experts are that treatment will help.

Which Medications Are Used?

Bile acid sequestrants (BAS) are the mainstay of treatment. These medications bind to bile acids in the intestine, preventing them from reaching the colon and causing diarrhoea.

Colestyramine was the first-line BAS used by 95% of respondents. Starting doses for a 70 kg woman varied considerably:

• 29% used 2 g once daily
• 38% used 4 g once daily
• 24% used 4 g twice daily
• 10% used 4 g three times daily

Colesevelam was the main alternative, with starting doses of:

• 29% starting with 625 mg once daily
• 24% with 1.25 g once daily
• 29% with 1.25 g twice daily
• 10% with 1.25 g three times daily or another regimen

There was a preference to give these drugs last thing at night (preferred by 38%) rather than with food (preferred by 29%).

76% of experts usually gave warnings to take other medications 1 hour before or 4 hours after the BAS, in order to avoid drug interactions. This is important because bile acid sequestrants can bind to other medications and reduce their absorption.

Managing Incomplete Response

What happens when a patient has an incomplete response to treatment? The experts had clear recommendations, and importantly, these did not differ much whether the patient had a SeHCAT result of 3% or 13%:

1. Increasing the dose—recommended by 100% of respondents
2. Adding loperamide (a medication that slows gut movement and reduces diarrhoea)—recommended by 80%
3. Changing to an alternative BAS (e.g., switching from colestyramine to colesevelam or colestipol)—recommended by 71%
4. Advice on a low fat diet (40 g/day)—recommended by 71%
5. Avoidance of high FODMAP foods (fermentable carbohydrates that can worsen gut symptoms)—recommended by 29%

Alternative drug therapies and dietary approaches are particularly relevant when the supply of BAS medication is interrupted, which has been a real-world problem patients have faced.

Expected Response Rates by Severity

The experts were asked to predict the response rate following optimisation of BAS therapy, based on their clinical experience, for each category of SeHCAT result. The findings are summarised in the table below, which shows the percentage of respondents predicting each response level:

In plain language: the more severe the BAD (lower SeHCAT retention), the better the predicted response to treatment. For severe disease (0%–5% retention), virtually all experts predicted a response rate above 70%, with 53% predicting more than 90% response. For moderate disease (5%–10%), 82% predicted at least a 70% response rate. In contrast, for borderline results (15%–20%), most experts predicted only 30%–50% response rates, and for normal results (>20%), no treatment response was expected.

Follow-Up and Improving Patient Experience

Good management doesn't end with prescribing a medication. The survey asked experts about follow-up care and how to improve the overall patient experience.

For follow-up of a typical patient treated with a BAS, the following approaches were given broadly similar importance:

• Annual review by a specialist (gastroenterologist) or GP
• Patient support groups
• Dietetic review (consulting a dietitian)
• Pharmacist review
• Monitoring of blood vitamins and lipids (fats/cholesterol) levels

To improve the overall patient experience, the majority of respondents considered these factors important:

• Greater recognition of BAD by various professional groups, particularly gastroenterologists
• More awareness in the popular press
• Greater recognition by GPs
• Improved diagnosis and better drugs

These findings highlight that BAD is not just about getting the right prescription—it requires ongoing care, monitoring, and awareness at multiple levels of the healthcare system.

Clinical Implications: What This Means for Patients

This expert survey has several important implications for patients living with chronic diarrhoea or IBS-D.

First, BAD is likely more common than most people realise. The experts recognised that a large proportion of patients diagnosed with IBS-D or functional diarrhoea actually have bile acid diarrhoea. If you have been diagnosed with IBS-D and your symptoms are not well controlled, it may be worth asking your doctor whether BAD testing could be appropriate for you.

Second, diagnosis can change everything. The survey clearly showed that experts prefer to confirm the diagnosis with SeHCAT testing before starting treatment. They recognised the value of a clear diagnosis rather than simply prescribing medication on a trial-and-error basis. Recent studies cited in the paper have shown that early SeHCAT testing has significant economic advantages, reducing unnecessary cross-sectional imaging (CT/MRI scans), repeated colonoscopies, and unnecessary trials of expensive medications. For patients, this means fewer invasive tests and a faster path to effective treatment.

Third, treatment is effective—especially for severe BAD. The predicted response rates are encouraging. For patients with severe BAD (SeHCAT retention below 5%), 100% of experts predicted treatment success rates over 70%, with more than half predicting over 90% response. Even for moderate disease, the vast majority of experts predicted good responses. If you have confirmed BAD, there is a strong chance that treatment will significantly improve your symptoms.

Fourth, there is a clear pathway for patients who don't respond fully. If the first medication doesn't work, experts recommend a step-by-step approach: increase the dose, add loperamide, switch to a different sequestrant, and consider a low fat diet. This means there are multiple options to try before giving up on treatment.

Fifth, treatment should be individualised. Starting doses vary widely among experts (from 2 g to 12 g daily of colestyramine, for example), and dosing at night is preferred by many. Your doctor may need to adjust the dose to find what works best for you.

Finally, international access remains a problem. SeHCAT is not licensed in the USA, which has hindered recognition of BAD globally. However, alternative tests such as blood measurements of C4 and FGF19, and faecal bile acid tests, are being developed and validated—particularly at the Mayo Clinic in the USA. These may eventually provide diagnostic options in settings where SeHCAT is unavailable.

Study Limitations: What This Survey Couldn't Prove

It's important to understand the limitations of this study when interpreting its findings.

The survey reflects opinion, not direct clinical data. While the experts had collectively treated over 1,000 patients, the survey asked for their opinions and predictions rather than analysing actual patient outcomes. The predicted response rates, for example, are based on clinical experience rather than a controlled trial.

The survey was limited to the UK. The experts all practice within the UK National Health Service, where SeHCAT testing is available and has been used extensively. Practice may differ in other countries where SeHCAT is not available, and where doctors rely on alternative diagnostic methods. The authors note, however, that the UK has greater experience of BAD diagnosis and management than most other countries precisely because of the wider use of SeHCAT.

The sample size was small. With only 21 respondents, all of whom were members of the UK-BARDN network with published research on BAD, the survey may not fully represent the views of all UK gastroenterologists. Other UK gastroenterologists who were not part of this network might have different opinions. The authors acknowledge this but note that where there is consensus among experts, the findings should still help inform future decisions and guidelines.

Experience with alternative tests was limited. The respondents had limited experience with faecal bile acid tests, C4, and FGF19, so these tests were not a major consideration in this survey. Previous research suggests that low C4 and high FGF19 can have a role in the diagnostic pathway and may help select patients for further testing, but these require further validation.

Recommendations: Actionable Advice for Patients

Based on this expert survey, here are practical recommendations for patients who may have bile acid diarrhoea, as well as for those already diagnosed:

If you have chronic diarrhoea and haven't been diagnosed:

1. Track your symptoms. Note stool frequency, consistency (using the Bristol Stool Form Scale), urgency, incontinence, and whether symptoms are constant or intermittent. This information will be invaluable for your doctor.
2. Ask about BAD testing. If you have been diagnosed with IBS-D or functional diarrhoea and your symptoms include loose stools more than three times a day, urgency, or incontinence, ask whether SeHCAT testing (or an alternative like C4 or FGF19 blood tests) might be appropriate.
3. Mention relevant medical history. If you've had gallbladder removal, bowel surgery (especially ileal resection or right hemicolectomy), Crohn's disease, pelvic radiotherapy, bariatric surgery, or a partial gastrectomy, tell your doctor—these are recognised associations with BAD.
4. Don't accept a "diagnosis" that doesn't explain your symptoms. The 5-year diagnostic delay highlighted in patient surveys is far too long. If treatment for IBS hasn't worked, push for further investigation.

If you have been diagnosed with BAD:

1. Start treatment as recommended. Colestyramine is the usual first-line treatment, but colesevelam (a tablet) is an alternative. Starting low and gradually increasing the dose is common practice.
2. Take your medication correctly. Many experts prefer dosing last thing at night. Take other medications at least 1 hour before or 4 hours after your BAS dose to avoid interactions.
3. If symptoms don't improve, speak up. Experts recommend increasing the dose, adding loperamide, switching to a different bile acid sequestrant, and trying a low fat diet (40 g/day). These strategies can be combined.
4. Consider dietary changes. A low fat diet was recommended by 71% of experts for incomplete response. Some experts (29%) also suggested avoiding high FODMAP foods.
5. Keep your follow-up appointments. Annual review with a specialist or GP, dietetic and pharmacist input, and monitoring of blood vitamins and lipids are all considered important parts of ongoing care.
6. Join patient support groups. These were highlighted as an important part of follow-up care, providing peer support and practical advice from others living with BAD.

Key takeaways:

• Bile acid diarrhoea is common, underdiagnosed, and treatable
• SeHCAT testing is the gold standard for diagnosis, with response rates predicted to be excellent in severe disease
• A large proportion of IBS-D patients may actually have BAD—testing can uncover the real cause of symptoms
• Multiple treatment options exist, and most patients respond well with appropriate optimisation

If any of this information resonates with your experience, consider discussing bile acid diarrhoea with your healthcare provider. This expert consensus shows that BAD is a well-recognised, diagnosable, and treatable condition—and that getting the right diagnosis can make a world of difference.

Frequently Asked Questions

What is bile acid diarrhoea (BAD)?

Bile acid diarrhoea occurs when excess bile acids reach the colon, causing watery stools, urgency, and frequent bowel movements. It can happen when the ileum fails to reabsorb bile acids or the liver makes too many. Recognised for over 50 years, it may be primary or secondary to surgery, Crohn's disease, or other conditions.

Who should be tested for bile acid diarrhoea?

Experts recommend testing for BAD in people with functional diarrhoea, irritable bowel syndrome with diarrhoea (IBS-D), or diarrhoea after gallbladder removal. Other associated conditions include ileal resection, Crohn's disease, right hemicolectomy, pelvic radiotherapy, microscopic colitis, bariatric surgery, and small intestinal bacterial overgrowth. If you have chronic loose stools and any of these, ask your doctor about testing.

How is bile acid diarrhoea diagnosed?

The preferred test is SeHCAT, a nuclear medicine scan that measures retention of a labelled bile acid over 7 days. Low retention confirms BAD. A therapeutic trial of a bile acid sequestrant is also used by 85% of experts. Blood tests for FGF19 or C4 are less commonly recognised but may aid diagnosis in some settings.

What does a SeHCAT test involve?

You swallow a capsule containing a small amount of radioactive selenium-labelled bile acid. A scan is done on day 1 and again on day 7 to see how much is retained. Low retention means excess bile acids are escaping into the colon, confirming BAD. It is safe and used widely in the UK.

What treatments are available for bile acid diarrhoea?

Bile acid sequestrants are first-line treatment, with colestyramine used by 95% of experts. Colesevelam is a common alternative. Starting doses vary, and many experts prefer dosing at night. Take other medications 1 hour before or 4 hours after the sequestrant to avoid interactions. Your doctor may adjust the dose.

What if treatment for bile acid diarrhoea doesn't fully work?

If symptoms persist, experts recommend: increasing the dose, adding loperamide, switching to an alternative bile acid sequestrant, and trying a low fat diet of 40g per day. Some also suggest avoiding high FODMAP foods. These steps can be combined and should be discussed with your healthcare provider.

I have chronic diarrhoea and was told I have IBS-D, but treatment isn't working. Should I get a second opinion about bile acid diarrhoea?

If you have been diagnosed with IBS-D or functional diarrhoea and your symptoms include frequent loose stools, urgency, or incontinence, a second opinion may be worthwhile. Bile acid diarrhoea is commonly overlooked, and diagnostic delays often exceed five years. A large proportion of IBS-D patients actually have bile acid diarrhoea, and SeHCAT testing can confirm it. Treatment with bile acid sequestrants is effective, with predicted response rates above 70% even for moderate disease. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original Article Title: Diagnosis and management of bile acid diarrhoea- a survey of UK expert opinion and practice

Authors: Julian R F Walters, Ramesh Arasaradnam, H Jervoise N Andreyev, for the UK Bile Acid Related Diarrhoea Network

Journal: Frontline Gastroenterology, 2020; volume 11, pages 358–363. Published Online First: 11 September 2019.

DOI: 10.1136/flgastro-2019-101301

Funding: The authors declared no specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

Peer Review Status: This article was peer-reviewed and published under the BMJ's CC BY-NC (non-commercial) open access license. The original authors have reported competing interests including grants and personal fees from GE Healthcare and other pharmaceutical companies, which are disclosed in the original publication.

Note: This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace professional medical advice. Always consult a qualified healthcare provider regarding diagnosis and treatment of your specific condition.